‘Plausibility’ and Admissibility of Post-Published Data in India
In May 2023, the UK Court of Appeal upheld the invalidity of Bristol-Myers Squibb’s Apaxiban patent for lacking “plausibility”. But how does this finding interact with the position of relevant laws in India? Responding to this question, we are pleased to bring to you this guest post by Amit Tailor, discussing whether the “plausibility” requirement is embedded within the Patent Act. Amit is a postgraduate in Pharmaceutical Sciences from National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali) […]
‘Plausibility’ and Admissibility of Post-Published Data in India Read More »








